Loading company…
Vilya uses machine learning to design molecular structures for drug development.
Founded in 2022, Vilya is a biotechnology company developing drugs designed to target disease biology. It uses machine learning and chemical space exploration to design molecular structures ranging from small molecules to antibodies. In August 2022, it raised USD 71 million in Series A funding led by ARCH Venture Partners, with NVentures, Menlo Ventures, Madrona Venture Group, LifeForce Capital, Altitude Life Science Ventures, and other investors participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in